EBMT 2017

1:24
Only the beginning of precision medicine and multiple myeloma.
Irene Ghobrial
1:47
Predicting and preventing clonal evolution in multiple myeloma
Irene Ghobrial
4:58
Concerns about using social media in oncology
Naveen Pemmaraju
4:01
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Sebastian Giebel
3:14
Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome
Maria Teresa Voso
1:26
Celluar therapy: a key part of EBMT 2017
Nicolaus Kröger
2:00
Updates on treatment methods for Hodgkin Lymphoma
Stephen Robinson
2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson
1:24
Treatment methods in mantle cell lymphoma
Stephen Robinson
3:26
What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau
6:43
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister
2:40
Can the cytomegalovirus be predicted by ELISpot assays?
Roy Chemaly
2:36
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben
3:44
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau
1:50
Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial
2:19
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals